The Clinical Assessment of Protease-Activated Receptor-2 Expression in Inflammatory Cells from Peripheral Blood and Bronchoalveolar Lavage Fluid in Idiopathic Pulmonary Fibrosis

被引:2
作者
Park, Young Sik [1 ]
Yoo, Chul-Gyu [1 ]
机构
[1] Seoul Natl Univ, Coll Med, Dept Internal Med & Lung Inst, Div Pulm & Crit Care Med, 101 Daehak Ro, Seoul 110744, South Korea
关键词
Receptor; PAR-2; Idiopathic Pulmonary Fibrosis; Bronchoalveolar Lavage;
D O I
10.4046/trd.2013.74.6.264
中图分类号
R56 [呼吸系及胸部疾病];
学科分类号
摘要
Background: Idiopathic pulmonary fibrosis (IPF) is a lethal pulmonary fibrotic disease. In general, the exaggerated activation of the coagulation cascade has been observed during initiation or maintenance of the fibrotic disease. In our recent study, immunohistochemical expression of protease-activated receptor-2 (PAR-2), which plays a key role in coagulation cascade, was observed in surgical specimen of IPF patients, and associated with poor clinical outcome. The aim of this study was to evaluate the overexpression of PAR-2 in inflammatory cells from peripheral blood and bronchoalveolar lavage fluid in IPF patients. Methods: From May 2011 to March 2012, IPF patients and controls were enrolled in Seoul National University Hospital. Peripheral blood and bronchoalveolar lavage fluid were collected for analysis of PAR-2 expression. Flow cytometry and reverse transcription polymerase chain reaction were used for PAR-2 receptor and mRNA assessment. Results: Twelve IPF patients and 14 controls were included in this study. Among them, flow cytometry analysis was conducted from 26 peripheral blood (patient group, 11; control group, 13) and 7 bronchoalveolar lavage fluid (patient group, 5; control group, 2). The expression of PAR-2 receptor was not different between patient and control groups (p=0.074). Among all 24 population, PAR-2 mRNA assessment was performed in 19 persons (patient group, 10; control group, 9). The mRNA expression of PAR-2 was not significant different (p=0.633). Conclusion: In IPF patients, PAR-2 receptor and mRNA expression were not different from control group.
引用
收藏
页码:264 / 268
页数:5
相关论文
共 20 条
[1]  
American Thoracic Society
[2]  
European Respiratory Society, 2002, AM J RESP CRIT CARE, V165, P277, DOI DOI 10.1164/AJRCCM.165.2.ATS01
[3]   Protease-Activated Receptor-2 Induces Myofibroblast Differentiation and Tissue Factor Up-Regulation during Bleomycin-Induced Lung Injury Potential Role in Pulmonary Fibrosis [J].
Borensztajn, Keren ;
Bresser, Paul ;
van der Loos, Chris ;
Bot, Ilze ;
van den Blink, Bernt ;
den Bakker, Michael A. ;
Daalhuisen, Joost ;
Groot, Angelique P. ;
Peppelenbosch, Maikel P. ;
von der Thusen, Jan H. ;
Spek, C. Arnold .
AMERICAN JOURNAL OF PATHOLOGY, 2010, 177 (06) :2753-2764
[4]   IPF: New insight in diagnosis and prognosis [J].
Caminati, Antonella ;
Harari, Sergio .
RESPIRATORY MEDICINE, 2010, 104 :S2-S10
[5]   Procoagulant signalling mechanisms in lung inflammation and fibrosis: novel opportunities for pharmacological intervention? [J].
Chambers, R. C. .
BRITISH JOURNAL OF PHARMACOLOGY, 2008, 153 :S367-S378
[6]  
D'Andrea MR, 1998, J HISTOCHEM CYTOCHEM, V46, P157
[7]  
Gunther A, 2000, AM J RESP CRIT CARE, V161, P454
[8]   Idiopathic pulmonary fibrosis [J].
Harari, S ;
Caminati, A .
ALLERGY, 2005, 60 (04) :421-435
[9]   ROLE OF THROMBIN IN PULMONARY FIBROSIS [J].
HERNANDEZRODRIGUEZ, NA ;
CAMBREY, AD ;
HARRISON, NK ;
CHAMBERS, RC ;
GRAY, AJ ;
SOUTHCOTT, AM ;
DUBOIS, RM ;
BLACK, CM ;
SCULLY, MF ;
MCANULTY, RJ ;
LAURENT, GJ .
LANCET, 1995, 346 (8982) :1071-1073
[10]   Tissue factor expression and fibrin deposition in the lungs of patients with idiopathic pulmonary fibrosis and systemic sclerosis [J].
Imokawa, S ;
Sato, A ;
Hayakawa, H ;
Kotani, M ;
Urano, T ;
Takada, A .
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 1997, 156 (02) :631-636